Opal Wealth Advisors’s GT Biopharma GTBP Stock Holding History

Opal Wealth Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-3,272	Closed	-$40.1K	–	234
2026 Q2	$40.1K	Buy	+3,272	New	+$33.2K	0.01%	223

Other funds holding GTBP

Main Street Group Glen Allen, Virginia $445M AUM 22.95% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

West Financial Advisors Des Moines, Iowa $665M AUM 10.35% 1-Year Est. Return

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Reyes Financial Architecture San Diego, California $162M AUM 20.04% 1-Year Est. Return

Opal Wealth Advisors's GTBP Position: Q3 2026 in Review

Opal Wealth Advisors sold out of GT Biopharma (GTBP) in Q3 2026, closing a stake of 3,272 shares — an estimated $40.1K sold.

Opal Wealth Advisors first reported a position in GTBP in Q2 2026 and held it in 1 quarter. The position peaked at $40.1K in Q2 2026. 7 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

Opal Wealth Advisors reported no remaining GT Biopharma position as of Q3 2026 after selling out during the quarter.
Opal Wealth Advisors sold 3,272 GT Biopharma shares in Q3 2026, an estimated $40.1K.
Opal Wealth Advisors first reported a position in GT Biopharma in Q2 2026 and held it in 1 quarter.
Opal Wealth Advisors's GT Biopharma position peaked at $40.1K in Q2 2026.
7 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on Opal Wealth Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.